1'758 companies found
EsoCap AG
Basel · Since 2017
The core activity of EsoCap Biotech is the development of medical solutions for esophageal diseases. The company focuses on the clinical development of products and technologies to improve the quality of life for patients with esophageal diseases.
Essential Pharma Switzerland GmbH
Zug · Since 2021
The core activity of Essential Pharma is the acquisition, integration, optimization and maintenance of established, branded medicines, particularly those that are difficult to manufacture or treat rare diseases. The company focuses on the areas of Central Nervous System, Gastroenterology, Ophthalmology and rare diseases, and supplies patients in over 70 countries.
EXERIS BIO SA
Lugano · Since 2023
eyegnos consulting GmbH
Zug · Since 2023
The core activity of eye.gnos consulting is to advise and support pharmaceutical companies in the fields of ophthalmology and immunology, particularly in the development of medications and therapies for eye and immune-related diseases. This includes services such as clinical development, regulatory support, marketing and medical affairs, as well as the conduct of clinical trials and image analysis in ophthalmology.
F. Hoffmann-La Roche AG
Basel · Since 1989
FONDATION EUROVACC
Lausanne · Since 2002
The core activity of EuroVacc is the development of safe and effective vaccines against HIV and other infectious diseases through the promotion and support of international collaborations with leading vaccine researchers and developers in the public and private sectors.
Galepharm AG
Zurich · Since 1959
The core activity of Galepharm AG is the development, manufacture and marketing of prescription niche products, in particular medicines that are no longer produced by other companies due to low demand, but are essential for many patients. The company specializes in providing established medicines and works with international partners to do so.
GEISTER Medical (Swiss) AG
Lenzburg · Since 2023
Genetas AG
Delémont · Since 2007
Geneva Biotech Center (GBC) SA
Geneva · Since 2013
The core activity of Atopia Tx is the development of innovative therapies for asthma and allergic diseases, in particular the development of a first disease-modifying therapeutic for asthma and allergies based on a molecule from Helicobacter pylori.
Genevant Sciences GmbH
Basel · Since 2018
The core activity of Genevant Sciences is the development and delivery of technologies and platforms for nucleic acid delivery, particularly for the development of medicines based on lipid nanoparticle (LNP) technology. The company focuses on collaborating with leading pharmaceutical and biotechnology companies to leverage its platforms, technologies, and patents to develop new medicines for patients.
Giuffry SA
Cadempino · Since 2011
Giuffry SA offers outdoor adventure packages and training courses, including mountain climbing, paragliding, off‑road trips and winter events. The company also provides environmental surveying services and lists professional courses such as a LinkedIn course on its site.
GLAROPHARM AG
Mitlödi · Since 2006
H.E. ADVANCED NUTRITION SA
Lugano · Since 2013
The core activity of HE Advanced Nutrition SA is the research and production of nutraceutical and pharmaceutical products, particularly food supplements and medicines, with innovative formulations and the highest quality standards.
Henberg Chemie SA
Pregassona · Since 2017
Henberg Chemie SA is a trading company supplying active pharmaceutical ingredients (APIs), finished dosage formulations (FDF) and technology transfer services for the pharmaceutical sector. Services include partner identification, regulatory-document support (CEP/COS, ASMF/DMF, GMP), market and promotional studies, and project follow-up from sourcing to commercial requirements.
Hermeda AG
Lucerne · Since 2015
Highhunters GmbH
Chur · Since 2019
The core activity of Highhunters is the cultivation and sale of CBD-containing hemp flowers.
ILIS Institut and Laboratory Dr. Ivan Slacanin
Biel/Bienne · Since 2018
Immortal Oceans AG
Zug · Since 2023
ImmunSkills SA
Monthey · Since 2022
ImmunSkills SA develops allogenic cell‑based therapies for solid cancers, aiming to create a product using allogenic cells that can kill various cancer cells and modify the tumour microenvironment to reduce treatment resistance.
Outbound Leads by COHAGALeadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Discover LeadhubHow the search works, what each filter means, and how the results come together.
Source: Federal Statistical Office, UID register